Hepatitis C virus (HCV) infection and lymphoproliferative disorders
Several infectious agents have been associated with development of lymphoproliferative disorders. Among these is hepatitis C virus (HCV), which infects more than 200 million people worldwide. HCV infection has been linked to progression of type II mixed cryoglobulinemia (MC) syndrome and has also been suggested to contribute to development of B-cell non-Hodgkin's lymphoma (NHL). Mechanisms responsible for development of lymphoproliferative disorders among HCV-positive patients remain unclear. Accumulating evidence supports a model in which chronic stimulation of B-cells by antigens associated with HCV infection causes nonmalignant B-cell expansion that may evolve into B-cell NHL. The course of disease among HCV-positive B-cell NHL patients may be complicated by coinfection with other infectious agents. This possibility has been explored by studies that have investigated potential interactions between HCV and human immunodeficiency virus (HIV) as well as between HCV and Epstein-Barr virus (EBV). Further characterization of the mechanisms by which HCV promotes development of lymphoproliferative disorders may improve diagnosis, classification, and treatment of these conditions.
Libra
Massimo
M
Department of Biomedical Sciences, University of Catania, Italy. mlibra@unict.it
Gasparotto
Daniela
D
Gloghini
Annunziata
A
Navolanic
Patrick Michael
PM
De Re
Valli
V
Carbone
Antonino
A
D000998:Antiviral Agents / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000473:pathology*; D016174:Hepacivirus; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000209:etiology*; D008232:Lymphoproliferative Disorders / Q000209:etiology
D000998:Antiviral Agents